EDNRB and idiopathic pulmonary fibrosis: Emerging combination strategies address these limitations-dual ET-1/PDGF pathway inhibition with nintedanib reduces IPF lung function decline by 58% annually, and ginsenoside Rg3 synergizes with PD-1 inhibitors to enhance antitumor immunity via EDNRB upregulation, achieving 2.1-fold survival improvement in murine models (41).